DE3772485D1 - Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben. - Google Patents

Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben.

Info

Publication number
DE3772485D1
DE3772485D1 DE8787900856T DE3772485T DE3772485D1 DE 3772485 D1 DE3772485 D1 DE 3772485D1 DE 8787900856 T DE8787900856 T DE 8787900856T DE 3772485 T DE3772485 T DE 3772485T DE 3772485 D1 DE3772485 D1 DE 3772485D1
Authority
DE
Germany
Prior art keywords
methods
recombinant dna
dna sequences
vectors
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787900856T
Other languages
English (en)
Inventor
Harris Wilson
Robert Bebbington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
UCB Celltech Ltd
Original Assignee
University of Glasgow
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10591815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3772485(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Glasgow, Celltech R&D Ltd filed Critical University of Glasgow
Application granted granted Critical
Publication of DE3772485D1 publication Critical patent/DE3772485D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE8787900856T 1986-01-23 1987-01-23 Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben. Expired - Lifetime DE3772485D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868601597A GB8601597D0 (en) 1986-01-23 1986-01-23 Nucleotide sequences
PCT/GB1987/000039 WO1987004462A1 (en) 1986-01-23 1987-01-23 Recombinant dna sequences, vectors containing them and method for the use thereof

Publications (1)

Publication Number Publication Date
DE3772485D1 true DE3772485D1 (de) 1991-10-02

Family

ID=10591815

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787900856T Expired - Lifetime DE3772485D1 (de) 1986-01-23 1987-01-23 Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben.

Country Status (9)

Country Link
US (3) US5122464A (de)
EP (1) EP0256055B1 (de)
JP (1) JPH0732712B2 (de)
AT (1) ATE66693T1 (de)
AU (1) AU599081B2 (de)
CA (1) CA1338901C (de)
DE (1) DE3772485D1 (de)
GB (1) GB8601597D0 (de)
WO (1) WO1987004462A1 (de)

Families Citing this family (984)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JPH01243989A (ja) * 1988-03-23 1989-09-28 Toyo Jozo Co Ltd グルタミン合成酵素の遺伝情報を有するｄｎａおよびその用途
US5879936A (en) * 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
GB8809129D0 (en) * 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
JP3456992B2 (ja) * 1988-12-08 2003-10-14 デイモン・バイオテック・インコーポレーテッド 変異型ｄｈｆｒ遺伝子を使用した発現誘導方法
GB2237288A (en) * 1989-10-18 1991-05-01 Celltech Ltd Amplification of a heterologous gene in recombinant eukaryotic host cells
GB8924021D0 (en) * 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
US5747308A (en) * 1989-10-25 1998-05-05 Celltech Therapeutics Limited Recombinant DNA method
US5891693A (en) * 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5252523A (en) * 1991-10-09 1993-10-12 Corning Incorporated Bioabsorbable chlorophosphate glasses and bioabsorbable glass-polymer blends made therefrom
GB9209993D0 (en) 1992-05-08 1992-06-24 Munn Edward A Vaccines
GB9215834D0 (en) 1992-07-24 1992-09-09 Celltech Ltd Cell culture
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
DK0802800T3 (da) * 1993-08-12 2002-10-07 Neurotech Sa Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler
US5908623A (en) 1993-08-12 1999-06-01 Cytotherapeutics, Inc. Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
EP0753065B1 (de) 1994-03-29 2003-05-14 Celltech Therapeutics Limited Antikörper gegen e-selektin
AU697465B2 (en) 1994-11-02 1998-10-08 Research Foundation Of The State University Of New York, The Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
WO1997038123A1 (en) * 1996-04-05 1997-10-16 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US5776746A (en) * 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
WO1997046589A2 (en) 1996-06-07 1997-12-11 Neorx Corporation Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
JP2000517188A (ja) 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
EP2112166B1 (de) 1998-12-23 2018-11-21 Pfizer Inc. Humane monoklonale antikörper gegen ctla-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
AU770807B2 (en) 1999-01-11 2004-03-04 Merck Sharp & Dohme Corp. Interleukin-17 related mammalian cytokines. polynucleotides encoding them. uses
AU3501700A (en) 1999-02-26 2000-09-14 Human Genome Sciences, Inc. Human endokine alpha and methods of use
JP2002538167A (ja) 1999-03-03 2002-11-12 バイオジェン インコーポレイテッド 脂質の代謝および貯蔵を調節する方法
JP4488579B2 (ja) * 1999-03-30 2010-06-23 日本たばこ産業株式会社 モノクローナル抗体の製造方法
AU754808B2 (en) 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
DE60033530T2 (de) 1999-08-24 2007-10-31 Medarex Inc. Humane antikörper gegen ctla-4 und deren verwendungen
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AR027509A1 (es) 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1294949A4 (de) 2000-06-15 2004-08-25 Human Genome Sciences Inc Menschlicher tumornekrosefaktor delta und epsilon
KR101287395B1 (ko) 2000-06-16 2014-11-04 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US6852510B2 (en) * 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
KR20030064377A (ko) * 2000-08-11 2003-07-31 파브릴, 인크. Ｔ 세포 매개 병증을 개선시키기 위한 방법 및 조성물
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20020099183A1 (en) * 2000-08-23 2002-07-25 Pluschkell Stefanie Beate Process for the preparation of neutrophil inhibitory factor
JP4434580B2 (ja) 2000-11-28 2010-03-17 メディミューン，エルエルシー 予防及び治療のために抗ｒｓｖ抗体を投与／処方する方法
EP1355919B1 (de) 2000-12-12 2010-11-24 MedImmune, LLC Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
CN1854157B (zh) 2001-01-05 2013-01-02 辉瑞大药厂 胰岛素样生长因子i受体的抗体
HUP0303251A2 (hu) 2001-02-27 2003-12-29 Maxygen Aps Béta-interferon-szerű molekulák
AU2002322478A1 (en) * 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
AU2002257142B2 (en) 2001-04-13 2008-09-04 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2002092017A2 (en) 2001-05-16 2002-11-21 Albert Einstein College Of Medicine Of Yeshiva University Human antipneumococcal antibodies from non-human animals
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
KR20100120246A (ko) 2001-11-14 2010-11-12 센토코 오르토 바이오테크 인코포레이티드 항 ｉｌ-6 항체, 조성물, 방법 및 용도
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2472282A1 (en) 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
GB0200977D0 (en) * 2002-01-17 2002-03-06 Lonza Biologics Plc Glutamine-auxotrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
CN1296485C (zh) * 2002-01-17 2007-01-24 英国龙沙生物医药股份有限公司 能够产生蛋白质及能够在无谷氨酰胺的培养基上生长的谷氨酰胺营养缺陷型人类细胞
WO2003062395A2 (en) * 2002-01-18 2003-07-31 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
AU2003244516A1 (en) 2002-02-07 2003-09-02 Novozymes Delta Limited Hiv inhibiting proteins
ATE423217T1 (de) * 2002-03-01 2009-03-15 Siemens Healthcare Diagnostics Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
DE60329020D1 (de) * 2002-03-01 2009-10-08 Siemens Healthcare Diagnostics Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von körperflüssigkeiten
EP1497445A2 (de) * 2002-04-01 2005-01-19 Human Genome Sciences, Inc. Spezifisch an gmad bindende antikörper
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
US7371383B2 (en) 2002-04-12 2008-05-13 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
WO2003086459A1 (en) 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CA2490409A1 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
GB0216648D0 (en) * 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
AU2003264033A1 (en) 2002-08-10 2004-02-25 Biogen Idec Ma Inc. Nogo receptor antagonists
US20040265315A1 (en) * 2002-09-05 2004-12-30 Christine Dingivan Methods of preventing or treating T cell malignancies by administering CD2 antagonists
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
RS20050300A (en) 2002-10-16 2007-08-03 Euro-Celtique S.A., Antibodies that bind cell-associated ca 125/0772p and methods of use thereof
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
ZA200504866B (en) 2002-12-24 2006-11-29 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
EP1585546B1 (de) 2002-12-30 2008-08-06 Biogen Idec MA Inc. Kim-1-antagonisten und verwendung zur immunsystemmodulation
US7259002B2 (en) * 2003-01-21 2007-08-21 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
WO2004073656A2 (en) 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EA010055B1 (ru) 2003-03-19 2008-06-30 Байоджен Айдек Ма Инк. ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
EP2316487B1 (de) 2003-04-11 2014-06-11 MedImmune, LLC Rekombinante IL-9 Antikörper und ihre Verwendung
ES2368737T3 (es) 2003-04-23 2011-11-21 Medarex, Inc. Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
AU2004259727A1 (en) * 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases.
WO2005010163A2 (en) * 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP1660186B1 (de) 2003-08-18 2013-12-25 MedImmune, LLC Humanisierung von antikörpern
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
EP1682178B8 (de) 2003-11-04 2010-09-01 Novartis Vaccines and Diagnostics, Inc. Verfahren zur behandlung von krebs mit expression des cd40-antigens
PT1680141E (pt) 2003-11-04 2010-12-20 Novartis Vaccines & Diagnostic Métodos terapêuticos para tumores sólidos que expressam o antigénio de superfície celular cd40
EP2243492A1 (de) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Verwendung von antagonistischen-anti-CD40-monoklonalen Antikörpern zur Behandlung von multiplem Myelom
CA2544368C (en) 2003-11-04 2014-04-01 Chiron Corporation Methods of therapy for b cell-related cancers
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
LT2418220T (lt) 2003-12-10 2017-10-10 E. R. Squibb & Sons, L.L.C. Interferono-alfa antikūnai ir jų panaudojimas
MXPA06005941A (es) 2003-12-10 2006-08-23 Medarex Inc Anticuerpos ip-10 y sus usos.
US7371381B2 (en) * 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
PT2805728T (pt) 2003-12-23 2020-04-08 Genentech Inc Novos anticorpos anti-il13 e o uso dos mesmos
CN1947012A (zh) 2003-12-23 2007-04-11 瑞纳神经科学公司 激动剂抗－trkC抗体和使用其的方法
ES2362667T3 (es) 2004-01-09 2011-07-11 Pfizer Inc. ANTICUERPOS FRENTE A MAdCAM.
CA2553946C (en) 2004-02-06 2019-02-26 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
NZ548612A (en) 2004-02-09 2009-11-27 Human Genome Sciences Inc Albumin fusion proteins comprising tandem GLP-1
EP1726647B1 (de) 2004-03-19 2015-01-07 GenomIdea, Inc. Gen zur förderung des wachstums von gefässendothelzellen
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
AU2005231359A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses
KR20060135060A (ko) 2004-04-07 2006-12-28 리나트 뉴로사이언스 코퍼레이션 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
PT2662390T (pt) 2004-06-21 2017-10-09 Squibb & Sons Llc Anticorpos contra recetor 1 do interferão alfa e as suas utilizações
KR101239542B1 (ko) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
NZ552091A (en) 2004-07-16 2009-09-25 Pfizer Prod Inc Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
KR20070040824A (ko) 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법
DK1781321T3 (da) 2004-08-02 2014-04-14 Zenyth Operations Pty Ltd Fremgangsmåde til behandling af cancer, der omfatter en vegf-b-antagonist
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2585719A1 (en) 2004-11-08 2006-05-18 Schering Corporation Tumor association of mdl-1 and methods
PL1853718T3 (pl) 2005-02-15 2016-01-29 Univ Duke Przeciwciała anty-CD19 i zastosowania w onkologii
US20090110681A1 (en) 2005-03-08 2009-04-30 Pfizer, Inc. Anti-M-CSF Antibody Compositions
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
SI2567976T1 (sl) 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
EP3058955B1 (de) 2005-03-24 2019-05-29 Millennium Pharmaceuticals, Inc. Ov064-bindende antikörper und verfahren zu deren verwendung
WO2006110214A2 (en) * 2005-04-08 2006-10-19 Medimmune, Inc. Antibodies against mammalian metapneumovirus
DK1871418T3 (da) 2005-04-19 2014-06-10 Seattle Genetics Inc Humaniserede anti-cd70-bindende midler og anvendelser deraf
TW200724548A (en) 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
EP2444421A1 (de) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin-Antikörper
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
JP5047947B2 (ja) 2005-05-05 2012-10-10 デューク ユニバーシティ 自己免疫疾患のための抗ｃｄ１９抗体治療
SI2161336T1 (sl) 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
TW200716174A (en) 2005-05-19 2007-05-01 Centocor Inc Anti-MCP-1 antibodies, compositions, methods and uses
EP1893647A2 (de) 2005-06-23 2008-03-05 MedImmune, Inc. Antikörperformulierungen mit optimierten aggregations- und fragmentierungsprofilen
EP1896073B1 (de) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23-antikörper, zusammensetzungen, verfahren und verwendung
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
US8343928B2 (en) 2005-07-07 2013-01-01 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
US7482124B2 (en) * 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
JP2009504659A (ja) 2005-08-08 2009-02-05 オンコノン・リミテッド・ライアビリティ・カンパニー 抗体組成物、腫瘍性疾患の処置方法、および受胎能の調節方法
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
JP5161777B2 (ja) 2005-09-07 2013-03-13 アムジェン フレモント インク． アクチビン受容体様キナーゼ−１に対するヒトモノクローナル抗体
EP1762575A1 (de) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identifizierung Tumor-assoziierter Antigene für Diagnoseund Therapie
AU2006294663B2 (en) 2005-09-26 2012-03-22 Medarex, Inc. Human monoclonal antibodies to CD70
US20090246189A1 (en) 2005-11-04 2009-10-01 Biogen Idec Ma Inc. And Mclean Hospital Methods for Promoting Neurite Outgrowth and Survival of Dopaminergic Neurons
CA2624393C (en) 2005-11-04 2016-01-05 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
BRPI0618705B8 (pt) 2005-11-14 2021-05-25 Labrys Biologics Inc anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
EP1963369B1 (de) 2005-11-28 2013-05-15 Zymogenetics, Inc. Il-21-antagonisten
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
NZ598421A (en) 2005-12-02 2013-11-29 Biogen Idec Inc Treatment of Conditions Involving Demyelination
EP1954311A4 (de) 2005-12-07 2009-12-23 Medarex Inc Ctla-4-antikörper-dosierungseskalationstherapien
SG174783A1 (en) 2005-12-08 2011-10-28 Medarex Inc Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
PE20070998A1 (es) 2005-12-09 2007-10-09 Ucb Pharma Sa Moleculas de anticuerpo que tienen especificidad para la il-6-humana
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
KR101401159B1 (ko) 2005-12-12 2014-05-29 에프. 호프만-라 로슈 아게 가변 부위에 글리코실화를 가지는 아밀로이드 베타에 대한 항체
ES2517420T3 (es) 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
PT1981902E (pt) 2006-01-27 2015-11-02 Biogen Ma Inc Antagonistas dos recetores nogo
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
KR20090029184A (ko) 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항체 조성물 및 신생물성 질병의 치료 방법
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
TWI429658B (zh) 2006-06-07 2014-03-11 Bioalliance Cv 辨認癌症細胞上表現的ｃｄ４３與ｃｅａ之含碳水化合物抗原決定區的抗體及其使用方法
ES2427924T3 (es) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
PT2511301T (pt) 2006-08-04 2018-03-08 Medimmune Ltd Anticorpos humanos para erbb2
JP5256199B2 (ja) 2006-08-07 2013-08-07 テヴァ バイオファーマシューティカルズ ユーエスエー，インコーポレーティッド アルブミン−インスリン融合タンパク質
WO2008018641A1 (en) 2006-08-11 2008-02-14 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
AU2007283463B2 (en) 2006-08-11 2012-04-26 Csl Limited Treatment of pulmonary disease conditions
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
JP5476122B2 (ja) 2006-09-26 2014-04-23 ゲンマブ エー／エス Ｃｄ３８発現腫瘍の併用処置法
MX2009003306A (es) 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
JP2010507365A (ja) 2006-10-19 2010-03-11 メルク アンド カンパニー インコーポレイテッド 抗ＩＬ−１３Ｒα１抗体およびその使用
ES2658239T3 (es) 2006-10-19 2018-03-08 Csl Limited Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina-13
AU2007334264A1 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to BTLA and methods of use
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
CN101626782B (zh) 2006-12-01 2013-03-27 梅达雷克斯公司 结合cd22的人抗体及其用途
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
AU2007334456A1 (en) 2006-12-13 2008-06-26 Merck Sharp & Dohme Corp. Methods of cancer treatment with IGF1R inhibitors
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
EP2097534A4 (de) 2006-12-14 2010-05-12 Medarex Inc Cd70-bindende antikörper und ihre verwendungen
CL2007003661A1 (es) 2006-12-18 2008-07-18 Genentech Inc Regiones de cadena pesada variable y liviana variable; acidos nucleicos que las codifican; metodo de produccion; anticuerpos anti-notch3 que las comprenden; y uso de los anticuerpos para tratar enfermedades relacionadas con el receptor notch3.
AR064623A1 (es) * 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
CA2764852C (en) 2007-01-05 2018-09-18 University Of Zurich Method of providing disease-specific binding molecules and targets
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
GEP20125693B (en) 2007-01-09 2012-11-26 Biogen Idec Inc Sp35 antibodies and usage thereof
US9107884B2 (en) 2007-02-02 2015-08-18 Biogen Ma Inc. Use of semaphorin 6A for promoting myelination and oligodendrocyte differentiation
US8114606B2 (en) * 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
US8685666B2 (en) * 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
WO2008103475A1 (en) * 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
CA2678888C (en) 2007-02-21 2015-04-14 University Of Massachusetts Human antibodies against hepatitis c virus (hcv) and uses thereof
JP5357782B2 (ja) 2007-02-21 2013-12-04 バクシネックス インコーポレーティッド 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
DK2447719T3 (en) 2007-02-26 2016-10-10 Oxford Biotherapeutics Ltd proteins
EP1970384A1 (de) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
AU2008232902B2 (en) 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
WO2008134406A1 (en) * 2007-04-25 2008-11-06 The Board Of Trustees Of The Leland Stanford Junior University Ischemia-induced neovascularization is enhanced by hcns-sc transplantation
WO2008134046A1 (en) 2007-04-27 2008-11-06 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
WO2008137915A2 (en) 2007-05-07 2008-11-13 Medimmune, Llc Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2068927B1 (de) 2007-05-14 2015-10-21 MedImmune, LLC Verfahren zur reduzierung eosinophiler spiegel
EP1997832A1 (de) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
EP3255144A1 (de) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering-konstrukt zur herstellung von transgenen mäusen, die menschlische immunoglobulin erzeugen können
UA117446C2 (uk) 2007-08-29 2018-08-10 Санофі-Авентіс Гуманізоване антитіло до cxcr5
AU2008294074B2 (en) 2007-08-30 2015-01-22 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
AU2008296361B2 (en) 2007-09-04 2013-04-11 Compugen, Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US8530628B2 (en) 2007-09-28 2013-09-10 Welcome Receptor Antibodies Pty Ltd Diagnosis and treatment of diseased and damaged tissue
US20100297121A1 (en) * 2007-10-11 2010-11-25 Biogen Idec Ma Inc. Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
EP2215113B1 (de) 2007-10-26 2015-02-25 CSL Limited Cytokin-muteine
KR20100091170A (ko) 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법
BRPI0819195A2 (pt) 2007-11-05 2017-05-23 Medimmune Llc métodos para tratar escleroderma em um paciente em necessidade de tal tratamento e para aliviar um ou mais dos sintomas associados com escleroderma em um paciente em necessidade de tal tratamento.
EA026990B1 (ru) 2007-11-07 2017-06-30 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческой клеткой dec-205
EP2217625B1 (de) 2007-11-08 2021-08-04 Precision Biologics, Inc. Rekombinante monoklonale antikörper und entsprechende antigene für kolon- und pankreaskarzinom
US20110123553A1 (en) * 2007-11-08 2011-05-26 Biogen Idec Ma Inc. Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
ES2566963T3 (es) 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
KR101615215B1 (ko) 2007-12-07 2016-04-25 지모제넥틱스, 인코포레이티드 항-사람 ｉｌ-21 단클론성 항체
DK2222706T4 (en) 2007-12-14 2016-11-21 Novo Nordisk As Antibodies that bind to NKG2D and its use
WO2009077993A2 (en) 2007-12-17 2009-06-25 Pfizer Limited Treatment of interstitial cystitis
AU2008338313B2 (en) 2007-12-18 2014-01-16 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
JP5677703B2 (ja) 2008-01-10 2015-02-25 リサーチ ディベロップメント ファウンデーション Ｅｈｒｌｉｃｈｉａｃｈａｆｆｅｅｎｓｉｓにのためのワクチンおよび診断
EP2244729B1 (de) 2008-01-18 2016-11-02 MedImmune, LLC Cystein-manipulierte antikörper zur stellenspezifischen konjugation
BRPI0907640A2 (pt) 2008-01-25 2015-11-03 Univ Aarhus inibição exosítio-seletiva da atividade de papp-a contra igfbp-4
EP2240203B1 (de) 2008-02-05 2014-04-09 Bristol-Myers Squibb Company Alpha-5-beta-1-antikörper und ihre verwendungen
HUE028958T2 (en) 2008-02-08 2017-01-30 Medimmune Llc Anti-IFNAR1 antibodies with reduced Fc ligand affinity
EP2252317B1 (de) 2008-02-15 2014-04-09 Tufts University Behandlung von makuladegeneration
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
US20090269786A1 (en) * 2008-04-25 2009-10-29 The Board Of Trustees Of The University Of Illinois RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
JP2011526892A (ja) 2008-06-30 2011-10-20 アンジオブラスト システムズ，インコーポレーテッド 併用療法を使用した眼疾患及び過剰血管新生の治療
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8563697B2 (en) 2008-08-14 2013-10-22 Cephalon Australia Pty. Ltd. Anti-IL-12/IL-23 antibodies
JP5611210B2 (ja) 2008-09-07 2014-10-22 グリコネックス インコーポレイテッド 抗拡張ｉ型スフィンゴ糖脂質抗体、その誘導体および使用
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
EP2166021A1 (de) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
US8278419B2 (en) 2008-10-31 2012-10-02 Centocor Ortho Biotech Inc. Fibronectin type III domain based scaffold compositions, methods and uses
EP2358392B1 (de) 2008-11-12 2019-01-09 MedImmune, LLC Antikörper-formulierung
CA2745492A1 (en) 2008-12-08 2010-06-17 Compugen Ltd. A polyclonal or monoclonal antibody or antibody binding fragment that binds to a tmem154 polypeptide
SI2370466T1 (sl) 2008-12-19 2015-11-30 Biogen International Neuroscience Gmbh Človeška avtoprotitelesa proti alfa-sinukleinu
EP3187581A1 (de) * 2008-12-23 2017-07-05 BOCO Silicon Valley, Inc. Zielpopulationen von oligodendrozyten-vorläuferzellen und verfahren zur herstellung und verwendung davon
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
JP5766124B2 (ja) 2009-01-21 2015-08-19 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
US20120058131A1 (en) 2009-01-21 2012-03-08 Oxford Biotherapeutics Ltd Pta089 protein
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
DK2396011T3 (en) 2009-02-12 2016-04-25 Janssen Biotech Inc Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
WO2010094499A1 (en) 2009-02-20 2010-08-26 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
ES2639026T3 (es) 2009-03-05 2017-10-25 Oxford Biotherapeutics Ltd. Anticuerpos totalmente humanos específicos para CADM1
RU2542394C2 (ru) 2009-03-24 2015-02-20 ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. Гуманизированные антитела против light и их применение
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
EP2414507B1 (de) 2009-04-03 2014-07-02 Medical Research Council Mutanten von aktivierungsinduzierter cytidin-deaminase (aid) und verwendungsverfahren
UA108201C2 (xx) 2009-04-20 2015-04-10 Антитіла, специфічні для кадгерину-17
WO2010123994A1 (en) * 2009-04-23 2010-10-28 Neurotech Usa, Inc. Cell lines that produce prostaglandin f2 alpha (pgf2a) and uses thereof
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
MA33279B1 (fr) 2009-04-27 2012-05-02 Novartis Ag Compositions et procédés pour l'augmentation de la croissance des muscles
EA201101572A1 (ru) 2009-04-27 2012-05-30 Новартис Аг Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
KR20120088550A (ko) 2009-05-04 2012-08-08 애보트 리서치 비.브이. 증진된 생체내 안정성을 갖는 신경 성장 인자(ｎｇｆ)에 대한 항체
PT2427212T (pt) 2009-05-08 2017-11-20 Vaccinex Inc Anticorpos anti-cd100 e métodos para utilização dos mesmos
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
BRPI1011805A2 (pt) 2009-06-18 2016-10-11 Pfizer anticorpos anti incisura-1
JP5918129B2 (ja) 2009-06-22 2016-05-18 メディミューン，エルエルシー 部位特異的共役のための操作されたＦｃ領域
EP2456790A1 (de) 2009-07-20 2012-05-30 Bristol-Myers Squibb Company Kombination aus einem anti-ctla4-antikörper mit verschiedenen therapien für die synergistische behandlung proliferativer erkrankungen
AU2010276580A1 (en) 2009-07-31 2012-03-15 Medarex, L.L.C. Fully human antibodies to BTLA
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
US8822214B2 (en) 2009-09-15 2014-09-02 Medimmune Limited Cells for transient expression and uses thereof
CA2773552C (en) 2009-09-15 2017-11-21 Csl Limited Treatment of neurological conditions
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2488553B1 (de) 2009-10-12 2015-06-17 Pfizer Inc. Krebsbehandlung
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
NZ623607A (en) 2009-10-23 2016-07-29 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
WO2011056073A2 (en) 2009-11-04 2011-05-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
EP2322555A1 (de) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antikörper spezifisch für Claudin 6 (CLDN6)
CN102741289B (zh) 2009-11-11 2016-08-03 加尼梅德药物公司 密蛋白6(cldn6)特异性的抗体
EP2325322A1 (de) 2009-11-23 2011-05-25 4-Antibody AG Retrovirusvektorpartikel und Verfahren zu deren Erzeugung und Verwendung
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
SA114360064B1 (ar) 2010-02-24 2016-01-05 رينات نيوروساينس كوربوريشن طرق وأجسام مضادة معارضة ضد مستقبل il-7
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
AU2011227335B2 (en) 2010-03-17 2014-11-06 Abbott Research B.V. Anti-nerve growth factor (NGF) antibody compositions
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
EP2371864A1 (de) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
WO2011123507A1 (en) 2010-03-30 2011-10-06 Centocor Ortho Biotech Inc. Humanized il-25 antibodies
CA2796571C (en) 2010-04-13 2019-10-29 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
PL3202789T3 (pl) 2010-04-16 2020-09-21 Biogen Ma Inc. Przeciwciała anty-vla-4
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
JP6093696B2 (ja) 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
WO2011163558A1 (en) 2010-06-25 2011-12-29 Abbott Laboratories Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies
EP2404936A1 (de) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Krebstherapie mittels CLDN6-zielgerichteter Antikörper im lebenden Organismus
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
AU2011293127B2 (en) 2010-08-27 2016-05-12 Abbvie Stemcentrx Llc Notum protein modulators and methods of use
BR112013005145B1 (pt) 2010-09-02 2022-02-15 Vaccinex, Inc Anticorpo isolado ou seu fragmento de ligação ao antígeno que se liga especificamente ao cxcl13, composição e uso de uma composição
AU2011295715B9 (en) 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
RU2551963C2 (ru) 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
EP2616100B1 (de) 2010-09-17 2016-08-31 Compugen Ltd. Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
JP2013543384A (ja) 2010-10-05 2013-12-05 ノバルティス アーゲー 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
ES2686550T3 (es) 2010-10-11 2018-10-18 Biogen International Neuroscience Gmbh Anticuerpos anti-tau humanos
EP2635607B1 (de) 2010-11-05 2019-09-04 Zymeworks Inc. Design stabiler heterodimerer antikörper mit mutationen in der fc-domäne
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
BR112013014119A8 (pt) 2010-12-08 2017-07-11 Stem Centrx Inc Novos moduladores e métodos de uso
MX346995B (es) 2010-12-15 2017-04-06 Wyeth Llc Anticuerpos anti-notch1.
AU2011343161B2 (en) 2010-12-17 2017-02-02 Neurimmune Holding Ag Human anti-SOD1 antibodies
EP3211001B1 (de) 2010-12-22 2020-10-07 The Board of Trustees of the Leland Stanford Junior University Superagonisten und antagonisten von interleukin-2
AU2011352207B2 (en) 2010-12-31 2016-03-03 Bioatla, Llc Comprehensive monoclonal antibody generation
CA2823044C (en) 2010-12-31 2022-08-16 Jay M. Short Express humanization of antibodies
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
AR085911A1 (es) 2011-03-16 2013-11-06 Sanofi Sa Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
JP2014517685A (ja) 2011-04-15 2014-07-24 コンピュゲン エルティーディー． 免疫関連疾患およびがんの治療のためのポリペプチドおよびポリヌクレオチドならびにそれらの使用
WO2012145183A2 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
PL3026064T3 (pl) 2011-05-13 2019-05-31 Ganymed Pharmaceuticals Gmbh Przeciwciała do leczenia nowotworu z ekspresją klaudyny 6
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
MX349886B (es) 2011-06-10 2017-08-17 Medimmune Llc Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
GEP201706667B (en) 2011-06-28 2017-05-25 Berlin - Chemie Ag Antibodies to adp-ribosyl cyclase 2
PT2726094T (pt) 2011-06-28 2017-02-10 Oxford Biotherapeutics Ltd Alvo terapêutico e de diagnóstico
MX358726B (es) 2011-06-29 2018-09-03 Amgen Inc Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
EP2726503B1 (de) 2011-06-30 2019-09-04 Compugen Ltd. Polypetide und ihre verwendung zur behandlung von autoimmunerkrankungen und infektionen
US9365651B2 (en) 2011-07-01 2016-06-14 Novartis Ag Method for treating metabolic disorders by administration of an anti-ActRIIB antibody
CA2840460C (en) 2011-07-11 2022-08-16 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
CN103906535B (zh) 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
AU2012306341B2 (en) 2011-09-09 2017-08-31 Cambridge Enterprise Limited Anti-Siglec-15 antibodies and uses thereof
KR102225422B1 (ko) 2011-09-30 2021-03-08 다나-파버 캔서 인스티튜트 인크. 치료 펩티드
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
US9316645B2 (en) 2011-10-07 2016-04-19 Brown University Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
AU2012332587B2 (en) 2011-11-01 2017-02-23 Bionomics, Inc. Antibodies and methods of treating cancer
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
HUE050985T2 (hu) 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
EP2776467A1 (de) 2011-11-08 2014-09-17 Pfizer Inc Verfahren zur behandlung von entzündungserkrankungen mit anti-m-csf-antikörpern
EP2776470A2 (de) 2011-11-11 2014-09-17 Rinat Neuroscience Corporation Für trop-2 spezifische antikörper und ihre verwendungen
WO2013078118A1 (en) 2011-11-21 2013-05-30 Bristol-Myers Squibb Company Methods for determining the susceptibility of a virus to an attachment inhibitor
KR20140102710A (ko) 2011-12-22 2014-08-22 리나트 뉴로사이언스 코프. 인간 성장 호르몬 수용체 길항제 항체 및 그의 사용 방법
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
CA2848985A1 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
CN108324943B (zh) 2012-02-10 2024-03-08 思进股份有限公司 Cd30+癌症的检测和治疗
EP3093294A1 (de) 2012-02-24 2016-11-16 Stemcentrx, Inc. Dll3-antikörper und verfahren zur verwendung
US9567577B2 (en) 2012-03-12 2017-02-14 Ares Trading S.A. Expression vector comprising a polynucleotide encoding a modified glutamine synthetase and a method for preparing a target protein employing the same
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
SG11201406414WA (en) 2012-04-11 2014-11-27 Us Health Chimeric antigen receptors targeting b-cell maturation antigen
CA2910320A1 (en) 2012-04-26 2013-10-31 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
EP2848687B1 (de) * 2012-04-27 2017-09-13 JCR Pharmaceuticals Co., Ltd. Neuartiger expressionsvektor
ES2729729T3 (es) 2012-05-07 2019-11-05 Astellas Pharma Inc Anticuerpos que se unen a PLAC1 y bloquean la interacción entre PLAC1 y FGF7
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
ES2843054T3 (es) 2012-05-10 2021-07-15 Zymeworks Inc Construcciones heteromultiméricas de cadenas pesadas de inmunoglobulina con mutaciones en el dominio Fc
MX2014013950A (es) 2012-05-14 2015-02-17 Biogen Idec Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
DK3254695T3 (da) 2012-05-23 2020-11-30 Astellas Pharma Inc Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
EP3725810B1 (de) 2012-05-23 2022-07-06 Astellas Pharma Inc. Kombinationstherapie mit antikörpern gegen claudin 18.2 zur behandlung von krebs
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
MX362394B (es) 2012-06-08 2019-01-15 Glenmark Pharmaceuticals Sa Anticuerpos anti-trka humanizados con sustituciones de aminoacidos.
WO2013188182A1 (en) 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
EP2674495A1 (de) 2012-06-14 2013-12-18 Sanofi CHO-Expressionssystem
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP6498601B2 (ja) 2012-07-13 2019-04-10 ザイムワークス，インコーポレイテッド 多価ヘテロ多量体足場設計および構築物
EP4063391A1 (de) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit-antikörper und verwendungen davon
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
JP2015534564A (ja) 2012-10-09 2015-12-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 脱髄障害の治療のための併用療法および使用
WO2014062535A1 (en) 2012-10-15 2014-04-24 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
MX2015005874A (es) 2012-11-09 2015-09-10 Pfizer Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
MX369276B (es) 2012-11-13 2019-11-04 Biontech Ag Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
WO2014075697A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
EP3766903A3 (de) 2012-11-13 2021-02-17 BioNTech SE Bispezifischer antikörper anti claudin xcd3 zur behandlung von krebserkrankungen mit claudin-expression
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
CA2892756C (en) 2012-12-07 2020-04-14 Pfizer Inc. Engineered monomeric antibody fragments
HUE047221T2 (hu) 2012-12-17 2020-04-28 Trillium Therapeutics Inc A CD47+ kóros sejtek kezelése SIRP alfa-FC fúziókkal
LT2935326T (lt) 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
EP2938631B1 (de) 2012-12-31 2018-12-19 Neurimmune Holding AG Rekombinante menschliche antikörper zur therapie und vorbeugung von erkrankungen im zusammenhang mit polyomavirus
EA201591153A1 (ru) 2013-01-02 2016-01-29 Гленмарк Фармасьютикалс С.А. Антитела, связывающиеся с tl1a, и их применение
PL2953969T3 (pl) 2013-02-08 2020-02-28 Novartis Ag Przeciwciała anty-il-17a i ich zastosowanie w leczeniu zaburzeń autoimmunologicznych i zapalnych
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2956169B1 (de) 2013-02-12 2018-04-11 THE UNITED STATES OF AMERICA, represented by the S Monoklonale antikörper zur neutralisierung von noroviren
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
RS63738B1 (sr) 2013-02-20 2022-12-30 Astellas Pharma Inc Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
RS58873B1 (sr) 2013-02-22 2019-08-30 Abbvie Stemcentrx Llc Antidll3-antitelo-pbd konjugati i njihova upotreba
US9944992B2 (en) 2013-03-15 2018-04-17 The University Of Chicago Methods and compositions related to T-cell activity
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
WO2014152232A2 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
GB2525568B (en) 2013-03-15 2020-10-14 Abvitro Llc Single cell barcoding for antibody discovery
EP3666886A1 (de) 2013-03-15 2020-06-17 Dana-Farber Cancer Institute, Inc. Therapeutische peptide
EP2976360B1 (de) 2013-03-18 2019-11-27 Astellas Pharma Inc. Therapie mit antikörpern gegen claudin 18.2 zur behandlung von krebs
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
EP2981821B2 (de) 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunhistochemischer test zum nachweis der expression des liganden 1 für programmierten zelltod (pd-l1) in tumorgewebe
US20160053023A1 (en) 2013-04-09 2016-02-25 Annexon, Inc. Methods of treatment for neuromyelitis optica
DK2992017T3 (da) 2013-05-02 2021-01-25 Anaptysbio Inc Antistoffer rettet mod programmeret død-1 (pd-1)
CN105189560A (zh) 2013-05-07 2015-12-23 瑞纳神经科学公司 抗胰高血糖素受体抗体和其使用方法
EP2994164B1 (de) 2013-05-08 2020-08-05 Zymeworks Inc. Bispezifische her2- und her3-antigenbindende konstrukte
EP3583950A1 (de) 2013-05-09 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Single-domain-vhh-antikörper gegen norovirus gi.1 und gii.4 und deren verwendung
CA2912542A1 (en) 2013-05-13 2014-11-20 Tufts University Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
CA2922704A1 (en) 2013-05-24 2014-11-27 Neil R. Cashman Cell senescence markers as diagnostic and therapeutic targets
SG10201708143QA (en) 2013-06-06 2017-11-29 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
EP3008091A1 (de) 2013-06-13 2016-04-20 Fast Forward Pharmaceuticals B.V. Cd40-signalweghemmer und weitere verbindung, wobei die weitere verbindung eine gallensäure, ein gallensäurederivat, ein tgr5-rezeptoragonist, ein fxr-agonist oder eine kombination daraus ist, zur behandlung von chronischen entzündungen und zur vorbeugung von magen-darm-krebs oder fibrose
AU2014302082B2 (en) 2013-06-28 2019-08-08 Baylor Research Institute Dendritic cell ASGPR targeting immunotherapeutics for multiple sclerosis
SG10201710758PA (en) 2013-07-09 2018-02-27 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
EP3738612A1 (de) 2013-07-31 2020-11-18 Biontech AG Diagnose und therapie von krebs mit krebsstammzellen
TWI671317B (zh) 2013-08-02 2019-09-11 輝瑞大藥廠 抗ｃｘｃｒ４抗體及抗體-藥物結合物
CN105960414A (zh) 2013-08-14 2016-09-21 诺华股份有限公司 治疗散发性包涵体肌炎的方法
PT3041507T (pt) 2013-08-26 2021-07-26 Biontech Res And Development Inc Ácidos nucleicos que codificam anticorpos humanos para sialil-lewis
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
CN105848671B (zh) 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 位点特异性抗体缀合方法和组合物
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
CN105848722B (zh) 2013-10-02 2021-09-03 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
EP2868328A1 (de) 2013-10-31 2015-05-06 Universitätsklinikum Regensburg Blockade Il-3 bei systemischem Lupus erythematosus und multipler Sklerose
IL245001B2 (en) 2013-11-13 2023-05-01 Pfizer Antibodies specific to cancer necrosis factor-like ligand 1a and preparations and their uses
AU2014360273A1 (en) 2013-12-06 2016-06-02 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
NZ720769A (en) 2013-12-09 2022-10-28 Allakos Inc Anti-siglec-8 antibodies and methods of use thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
BR112016014293B1 (pt) 2013-12-20 2023-11-21 Intervet International B.V Região de fragmento cristalizável canino, anticorpo caninizado, e,composição farmacêutica
CA2936366A1 (en) 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
KR20240049627A (ko) 2014-01-21 2024-04-16 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
EP2910645A1 (de) 2014-02-25 2015-08-26 STRATIFYER Molecular Pathology GmbH Verfahren und Zusammensetzungen zur Vorhersage der therapeutischen Wirksamkeit von Krebsbehandlungen und Krebsprognose bei Antikörperbehandlung
DK3110446T3 (da) 2014-02-28 2022-02-28 Allakos Inc Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
JP2017510631A (ja) 2014-03-14 2017-04-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 癌に対しｎｋｇ２ｄ経路機能を回復させるためのワクチン組成物および方法
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
WO2015153916A1 (en) 2014-04-04 2015-10-08 Bionomics, Inc. Humanized antibodies that bind lgr5
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
EP3134102B1 (de) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonisten, partielle agonisten und antagonisten von interleukin-2
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
SG10201809628SA (en) 2014-04-30 2018-11-29 Pfizer Anti-ptk7 antibody-drug conjugates
EP3143043B1 (de) 2014-05-16 2022-12-14 Pfizer Inc. Bispezifische antikörper mit modifizierten ch1-cl interaktionen
EP3888690A3 (de) 2014-05-16 2021-10-20 MedImmune, LLC Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
CN108064242B (zh) 2014-05-28 2022-10-21 阿吉纳斯公司 抗gitr抗体和其使用方法
AU2015270912B9 (en) 2014-06-02 2021-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting CD-19
HUE055189T2 (hu) 2014-06-04 2021-11-29 Biontech Res And Development Inc Humán monoklonális antitestek a GD2 ganglioziddal ellen
HUE047385T2 (hu) 2014-06-06 2020-04-28 Bristol Myers Squibb Co Antitestek glükokortikoid indukált tumornekrózis faktor receptor (GITR) ellen és annak felhasználásai
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN106661600B (zh) 2014-07-16 2021-04-06 唐恩生物科技股份有限公司 用于扩增核酸样品的等温方法
SG10201913611QA (en) 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
MA40460A (fr) 2014-08-11 2016-02-18 Shire Human Genetic Therapies Ciblage lysosomial et utilisation correspondante
MX2017002229A (es) 2014-08-19 2017-05-09 Merck Sharp & Dohme Anticuerpos anti tigit.
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
ES2895750T3 (es) 2014-09-15 2022-02-22 Abvitro Llc Secuenciación de alto rendimiento de colecciones de nucleótidos
IL250902B (en) 2014-09-16 2022-08-01 Symphogen As Anti-met antibodies and preparations
KR102594327B1 (ko) 2014-09-30 2023-10-27 뉴리뮨 홀딩 아게 인간-유래의 항-디펩티드 반복체(dpr) 항체
EP3201226A2 (de) 2014-10-03 2017-08-09 Massachusetts Institute of Technology Antikörper zur bindung von ebola-glycoprotein und verwendungen davon
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US11559801B2 (en) 2014-11-03 2023-01-24 Tangen Biosciences, Inc. Apparatus and method for cell, spore, or virus capture and disruption
US10316081B2 (en) 2014-11-05 2019-06-11 Annexon, Inc. Humanized anti-complement factor C1Q antibodies
TWI758928B (zh) 2014-11-21 2022-03-21 美商必治妥美雅史谷比公司 抗cd73抗體及其用途
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
WO2016090170A1 (en) 2014-12-05 2016-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A potent anti-influenza a neuraminidase subtype n1 antibody
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
PL3333191T3 (pl) 2014-12-11 2021-05-04 Pierre Fabre Médicament Przeciwciała przeciwko c10orf54 i ich zastosowania
CN113563468A (zh) 2014-12-19 2021-10-29 雷根尼桑斯公司 结合人c6的抗体及其用途
WO2016106221A1 (en) 2014-12-22 2016-06-30 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
CN107428813B (zh) 2014-12-31 2021-08-03 查克美特制药公司 组合肿瘤免疫疗法
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EP3242893A1 (de) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1-antagonisten und verwendungen zur behandlung von demyelinisierungserkrankungen
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
EP3256855B1 (de) 2015-02-13 2020-10-07 Quanterix Corporation Immunoassays zur differentiellen detektion von clostridium difficile
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
BR112017020054A2 (pt) 2015-03-23 2018-06-05 Jounce Therapeutics Inc anticorpos para icos
IL305207A (en) 2015-03-30 2023-10-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and their uses to prevent the outbreak of hereditary angioedema
MY190209A (en) 2015-03-31 2022-04-05 Medimmune Ltd A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
CA3232537A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
JP6871232B2 (ja) 2015-04-06 2021-05-12 サブドメイン リミテッド ライアビリティ カンパニー 新規結合ドメイン含有ポリペプチドおよびその使用
MX2017012802A (es) 2015-04-07 2018-04-11 Alector Llc Anticuerpos antisortilina y métodos para su uso.
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
CN107980046B (zh) 2015-04-13 2021-12-24 辉瑞公司 靶向b细胞成熟抗原的嵌合抗原受体
EP3283106B1 (de) 2015-04-13 2021-12-22 Pfizer Inc. Therapeutische antikörper und deren verwendungen
CN107847590B (zh) 2015-04-15 2022-07-26 安奈普泰斯生物有限公司 针对白细胞介素36受体(il-36r)的抗体
WO2016165765A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016170447A1 (en) 2015-04-24 2016-10-27 Rinat Neuroscience Corp. Recombinant microbial transglutaminases
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
PT3303394T (pt) 2015-05-29 2020-07-01 Ludwig Inst For Cancer Res Ltd Anticorpos anti-ctla-4 e métodos de uso dos mesmos
HUE056407T2 (hu) 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
EP3307771A2 (de) 2015-06-12 2018-04-18 Alector LLC Anti-cd33-antikörper und verfahren zur verwendung davon
EP3307779A2 (de) 2015-06-12 2018-04-18 Alector LLC Anti-cd33-antikörper und verfahren zur verwendung davon
AU2016278239B9 (en) 2015-06-17 2022-08-11 Allakos Inc. Methods and compositions for treating fibrotic diseases
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
EP3971211A1 (de) 2015-07-13 2022-03-23 Compugen Ltd. Hide1-zusammensetzungen und verfahren
CN116333144A (zh) 2015-07-21 2023-06-27 武田药品工业株式会社 一种因子xiia的单克隆抗体抑制剂
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
EP3337822A1 (de) 2015-08-19 2018-06-27 Rutgers, The State University of New Jersey Neuartige verfahren zur erzeugung von antikörpern
SG10201912817YA (en) 2015-08-19 2020-02-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
EP3341415B1 (de) 2015-08-28 2021-03-24 H. Hoffnabb-La Roche Ag Anti-hypusin-antikörper und verwendungen davon
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
IL258009B2 (en) 2015-09-15 2024-03-01 Univ Texas Antibodies that bind receptors on T cells (TCR) and their use
CA2999277A1 (en) 2015-09-21 2017-03-30 Surface Oncology, Inc. Anti-cd47 antibodies and methods of use
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
TWI751981B (zh) 2015-10-02 2022-01-11 丹麥商賽門弗鎮公司 抗pd-1抗體及組成物
SG10201912150TA (en) 2015-10-06 2020-02-27 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
AU2016337525B2 (en) 2015-10-16 2022-01-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
KR20180066236A (ko) 2015-10-22 2018-06-18 조운스 테라퓨틱스, 인크. Icos 발현을 계측하기 위한 유전자 특질
EP3365369A1 (de) 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2-antikörper sowie zusammensetzungen und verwendungen davon
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
JP7060502B2 (ja) 2015-10-29 2022-04-26 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－９抗体及びその使用方法
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
AU2016355568A1 (en) 2015-11-18 2018-06-21 Merck Sharp & Dohme Llc PD1/CTLA4 Binders
AU2016355569B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc CTLA4 binders
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US20180334493A1 (en) 2015-11-19 2018-11-22 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
WO2017084078A1 (en) 2015-11-19 2017-05-26 Zeling Cai Ctla-4 antibodies and uses thereof
KR102630475B1 (ko) 2015-11-30 2024-01-26 브리스톨-마이어스 스큅 컴퍼니 항 인간 ip-10 항체 및 이의 용도
EP3383418B1 (de) 2015-12-04 2021-10-20 Board of Regents, The University of Texas System Slc45a2-peptide für immuntherapie
AU2016366557B2 (en) 2015-12-11 2024-01-25 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN109069570A (zh) 2015-12-16 2018-12-21 默沙东公司 抗lag3抗体和抗原结合片段
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN108713026B (zh) 2016-01-08 2023-01-06 美国全心医药生技股份有限公司 四价抗psgl-1抗体及其用途
EP3405490B1 (de) 2016-01-21 2021-10-20 Pfizer Inc. Mono- und bispezifische antikörper für die rezeptorvarianten iii und cd3 des epidermalen wachstumsfaktors und deren verwendung
EA201891641A1 (ru) 2016-01-21 2019-01-31 Пфайзер Инк. Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
JP2019511911A (ja) 2016-02-17 2019-05-09 ノバルティス アーゲー Ｔｇｆベータ２抗体
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
AU2016394956B2 (en) 2016-03-04 2024-02-08 The Rockefeller University Antibodies to CD40 with enhanced agonist activity
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
CN109071614B (zh) 2016-03-08 2022-09-06 碁米库斯生物科技股份有限公司 肺炎球菌溶血素ply截短胜肽及其用途
KR102632796B1 (ko) 2016-03-10 2024-02-02 비엘라 바이오, 인크. Ilt7 결합 분자 및 이의 사용 방법
WO2017161414A1 (en) 2016-03-22 2017-09-28 Bionomics Limited Administration of an anti-lgr5 monoclonal antibody
US11034992B2 (en) 2016-03-23 2021-06-15 The General Hospital Corporation Assays and methods for detecting UDP-glucose
AU2017241776A1 (en) 2016-03-29 2018-10-11 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
WO2017178493A1 (en) 2016-04-12 2017-10-19 Symphogen A/S Anti-tim-3 antibodies and compositions
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
BR112018071276A2 (pt) 2016-04-27 2019-02-12 Pfizer Inc. anticorpos anti-il-33, composições, métodos e usos dos mesmos
BR112018072118A2 (pt) 2016-04-29 2019-03-19 Pfizer Inc. anticorpos de interferona beta e usos dos mesmos
KR102417687B1 (ko) 2016-05-09 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 Tl1a 항체 및 그의 용도
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
MA45123A (fr) 2016-05-27 2019-04-10 Agenus Inc Anticorps anti-tim-3 et leurs méthodes d'utilisation
US10851159B2 (en) 2016-06-02 2020-12-01 Bloom Diagnostics Ag Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
AU2017279548A1 (en) 2016-06-08 2018-12-13 Precigen, Inc. Cd33 specific chimeric antigen receptors
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
JP7149257B2 (ja) 2016-07-13 2022-10-06 バイオジェン・エムエイ・インコーポレイテッド Ｌｉｎｇｏ－１アンタゴニストの投与計画及び脱髄障害の処置のための使用
PE20190418A1 (es) 2016-07-14 2019-03-19 Bristol Myers Squibb Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
CN109715670A (zh) 2016-07-15 2019-05-03 波赛达治疗公司 对muc1特异性的嵌合抗原受体(car)及其使用方法
JP2019524721A (ja) 2016-07-15 2019-09-05 ポセイダ セラピューティクス， インコーポレイテッド キメラ抗原受容体および使用方法
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018037000A1 (en) 2016-08-23 2018-03-01 Medimmune Limited Anti-vegf-a and anti-ang2 antibodies and uses thereof
US10919958B2 (en) 2016-08-23 2021-02-16 Medimmune Limited Anti-VEGF-A antibodies and uses thereof
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018054484A1 (en) 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US20180094052A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibody
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
EP3519561A1 (de) 2016-09-30 2019-08-07 Poseida Therapeutics, Inc. Gedächtnis-t-zellen mit modifizierten stammzellen, verfahren zur herstellung und verfahren zur verwendung davon
WO2018068022A1 (en) 2016-10-06 2018-04-12 Poseida Therapeutics, Inc. Inducible caspases and methods for use
CN110023337B (zh) 2016-10-11 2024-01-05 艾吉纳斯公司 抗lag-3抗体及其使用方法
EP3526255A2 (de) 2016-10-13 2019-08-21 Symphogen A/S Anti-laf-3-antikörper-zusammensetzungen
CU20190036A7 (es) 2016-10-13 2019-11-04 Massachusetts Inst Technology Anticuerpos que se unen a la proteína de envoltura del virus zika
EP3532496A1 (de) 2016-10-28 2019-09-04 Banyan Biomarkers, Inc. Antikörper gegen ubiquitin c-terminale hydrolase l1 (uch-l1) und gliales fibrilläres saures protein (gfap) und verwandte verfahren
WO2018085469A2 (en) 2016-11-01 2018-05-11 Anaptysbio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
US11155624B2 (en) 2016-11-01 2021-10-26 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
HUE057559T2 (hu) 2016-11-02 2022-06-28 Jounce Therapeutics Inc PD-1 elleni antitestek és alkalmazásaik
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
MA46861A (fr) 2016-11-16 2019-09-25 Janssen Biotech Inc Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
EP3541841A1 (de) 2016-11-18 2019-09-25 Symphogen A/S Anti-pd-1-antikörper zusammensetzungen
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
AU2017373944B2 (en) 2016-12-07 2022-02-03 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
MX2019008208A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-tim-3.
KR102606252B1 (ko) 2017-01-09 2023-11-23 테사로, 인코포레이티드 항-pd-1 항체로 암을 치료하는 방법
JP7288401B2 (ja) 2017-01-10 2023-06-07 プレシゲン，インコーポレイテッド 新規の遺伝子スイッチ発現系を介したポリペプチドの発現のモジュレーション
CA3049656A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
WO2018133842A1 (zh) 2017-01-20 2018-07-26 大有华夏生物医药集团有限公司 人程序性死亡受体pd-1的单克隆抗体及其片段
KR20240038146A (ko) 2017-01-30 2024-03-22 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2018147915A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
US10828330B2 (en) 2017-02-22 2020-11-10 IO Bioscience, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
CA3054885A1 (en) 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof
IL269203B1 (en) 2017-03-13 2024-05-01 Poseida Therapeutics Inc Preparations and methods for the selective elimination and replacement of hematopoietic stem cells
JP7177076B2 (ja) 2017-03-16 2022-11-22 ファイザー・インク チロシン原栄養性
WO2018175460A1 (en) 2017-03-24 2018-09-27 Novartis Ag Methods for preventing and treating heart disease
WO2018187191A1 (en) 2017-04-03 2018-10-11 Jounce Therapeutics, Inc Compositions and methods for the treatment of cancer
EA201992350A1 (ru) 2017-04-05 2020-03-23 Симфоген А/С Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
WO2018189611A1 (en) 2017-04-12 2018-10-18 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
AU2018252546A1 (en) 2017-04-13 2019-10-10 Sairopa B.V. Anti-SIRPα antibodies
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
US20200399343A1 (en) 2017-04-19 2020-12-24 Allogene Therapeutics, Inc. Improved t cell compositions and methods
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
US11203629B2 (en) 2017-04-22 2021-12-21 Immunomic Therapeutics, Inc. LAMP constructs
US11760777B2 (en) 2017-04-26 2023-09-19 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
EP3618863B1 (de) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antikörper und deren verwendung
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
WO2018204868A1 (en) 2017-05-05 2018-11-08 Allakos Inc. Methods and compositions for treating allergic ocular diseases
MX2019013110A (es) 2017-05-05 2019-12-16 Vaccinex Inc Anticuerpo anti-semaforina 4d humano.
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2018213335A1 (en) 2017-05-16 2018-11-22 Scalmibio, Inc. Activatable antibodies and methods of use thereof
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
CA3063807A1 (en) 2017-05-18 2018-11-22 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
WO2018218222A1 (en) 2017-05-26 2018-11-29 Goldfless Stephen Jacob High-throughput polynucleotide library sequencing and transcriptome analysis
PE20191846A1 (es) 2017-06-02 2019-12-31 Pfizer Anticuerpos especificos para flt3 y sus usos
PE20191847A1 (es) 2017-06-02 2019-12-31 Pfizer Receptores de antigenos quimericos que se dirigen a flt3
CN110709415A (zh) 2017-06-02 2020-01-17 辉瑞大药厂 重组robo2蛋白、组合物、方法及其用途
IL306102A (en) 2017-06-07 2023-11-01 Precigen Inc Expression of new cell markers
EP3635008A1 (de) 2017-06-09 2020-04-15 Pfizer Inc Anti-robo2-antikörper, zusammensetzungen, verfahren und verwendungen davon
US11542312B2 (en) 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies
US11613588B2 (en) 2017-06-28 2023-03-28 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
US20200181271A1 (en) 2017-06-28 2020-06-11 Novartis Ag Methods for preventing and treating urinary incontinence
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
EP3652211A1 (de) 2017-07-14 2020-05-20 Pfizer Inc. Antikörper gegen madcam
WO2019018647A1 (en) 2017-07-20 2019-01-24 Pfizer Inc. ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
JP7299160B2 (ja) 2017-08-03 2023-06-27 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
TWI811229B (zh) 2017-08-03 2023-08-11 美商阿列克特有限責任公司 抗trem2抗體及其使用方法
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
CA3071966A1 (en) 2017-08-22 2019-02-28 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
MA50079A (fr) 2017-09-07 2020-07-15 Juno Therapeutics Inc Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
CN111727256A (zh) 2017-09-08 2020-09-29 波赛达治疗公司 用于嵌合配体受体（clr）-介导的条件性基因表达的组合物和方法
JP7023942B2 (ja) 2017-09-20 2022-03-03 豊宥科技股▲フン▼有限公司 卵巣癌バイオマーカーおよびその使用
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
CA3079788C (en) 2017-10-27 2023-09-05 Pfizer Inc. Antibodies and antibody-drug conjugates specific for cd123 and uses thereof
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
CN111295189B (zh) 2017-11-01 2023-09-15 艾洛基治疗公司 修饰的胱天蛋白酶-9多肽及其使用方法
BR112020008379A2 (pt) 2017-11-03 2020-11-03 Novartis Ag anticorpos anti-cd40 para uso no tratamento de síndrome de sjögren
AU2018369639A1 (en) 2017-11-14 2020-04-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
MX2020004935A (es) 2017-11-14 2020-09-25 Arcellx Inc Terapias con celulas inmunitarias multifuncionales.
MX2020005463A (es) 2017-12-01 2020-09-07 Seattle Genetics Inc Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
CN111615520A (zh) 2017-12-01 2020-09-01 辉瑞大药厂 抗cxcr5抗体及其组合物和用途
WO2019126574A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Vcar compositions and methods for use
AU2018389111A1 (en) 2017-12-22 2020-06-18 Jounce Therapeutics, Inc. Antibodies to LILRB2
JP7284759B2 (ja) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
EP3737700A1 (de) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antikörper gegen tim3 und verwendungen davon
AU2019215075A1 (en) 2018-02-01 2020-08-20 Pfizer Inc. Antibodies specific for CD70 and their uses
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
TW201936633A (zh) 2018-02-01 2019-09-16 美商輝瑞大藥廠 標靶至cd70的嵌合抗原受體
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019157447A1 (en) 2018-02-12 2019-08-15 Trustees Of Tufts College Cd59 for inhibiting inflammasome activation
EP3759129A1 (de) 2018-02-28 2021-01-06 Pfizer Inc Il-15-varianten und verwendungen davon
CA3091681A1 (en) 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
EA202091810A1 (ru) 2018-03-02 2021-01-29 Файв Прайм Терапьютикс, Инк. Антитела к b7-h4 и способы их применения
JP2021515770A (ja) 2018-03-05 2021-06-24 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ−２３特異的抗体を用いたクローン病の治療方法
CN112135622A (zh) 2018-03-06 2020-12-25 普莱西根股份有限公司 乙型肝炎疫苗及其用途
WO2019173636A1 (en) 2018-03-07 2019-09-12 Poseida Therapeutics, Inc. Cartyrin compositions and methods for use
CN111886256A (zh) 2018-03-23 2020-11-03 百时美施贵宝公司 抗mica和/或micb抗体及其用途
CA3094756A1 (en) 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof
US10640576B2 (en) 2018-04-10 2020-05-05 Y-Biologics Inc. Cell engaging binding molecules
US20210228729A1 (en) 2018-04-12 2021-07-29 Mediapharma S.R.L. Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
WO2019198019A1 (en) 2018-04-13 2019-10-17 Novartis Ag Anti-cd40 antibodies for use in prevention of graft rejection
US11459393B2 (en) 2018-04-17 2022-10-04 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
SG11202010019YA (en) 2018-04-20 2020-11-27 Janssen Biotech Inc Transition analysis method for chromatography column qualification
IL278400B2 (en) 2018-05-07 2024-03-01 Genmab As Combination of an anti-PD-1 antibody and conjugation of a drug with an anti-TF antibody for use in the treatment of cancer
WO2019217455A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
KR20240056644A (ko) 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
SG11202011201QA (en) 2018-05-11 2020-12-30 Wuxi Biologics Shanghai Co Ltd Fully human antibodies against ox40, method for preparing same, and use thereof
BR112020023167A2 (pt) 2018-05-14 2021-02-09 Werewolf Therapeutics, Inc. polipeptídeos de citocina ativáveis e métodos de uso destes
EP3794024B1 (de) 2018-05-14 2023-05-10 Werewolf Therapeutics, Inc. Aktivierbare interleukin-2-polypeptide und verfahren zu ihrer verwendung
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
PE20210488A1 (es) 2018-05-23 2021-03-15 Pfizer Anticuerpos especificos para gucy2c y sus usos
TWI793325B (zh) 2018-05-23 2023-02-21 美商輝瑞大藥廠 對cd3具特異性之抗體及其用途
WO2019232241A1 (en) 2018-05-30 2019-12-05 Abbvie Stemcentrx Llc Anti-sez6 antibody drug conjugates and methods of use
JP2021525806A (ja) 2018-06-01 2021-09-27 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 疾患または状態を処置するための組成物およびそれらの使用
CN112512638A (zh) 2018-06-08 2021-03-16 艾利妥 抗siglec-7抗体及其使用方法
WO2020003172A1 (en) 2018-06-26 2020-01-02 Mor Research Applications Transthyretin antibodies and uses thereof
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
CN111372655A (zh) 2018-07-13 2020-07-03 艾利妥 抗分拣蛋白抗体及其使用方法
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
WO2020023920A1 (en) 2018-07-27 2020-01-30 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
JP7155403B2 (ja) 2018-08-20 2022-10-18 ファイザー・インク 抗ｇｄｆ１５抗体、組成物および使用の方法
WO2020041360A1 (en) 2018-08-21 2020-02-27 Quidel Corporation Dbpa antibodies and uses thereof
KR20220036908A (ko) 2018-08-28 2022-03-23 보르 바이오파마 인크. 유전자 조작된 조혈 줄기 세포 및 그의 용도
JP2021535161A (ja) 2018-08-30 2021-12-16 ダイアックス コーポレーション 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
CA3111384A1 (en) 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
AU2019336197A1 (en) 2018-09-07 2021-02-18 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
RU2706298C1 (ru) 2018-09-14 2019-11-15 Закрытое Акционерное Общество "Биокад" НУКЛЕАЗА PaCas9
FI3883606T3 (fi) 2018-09-24 2023-09-07 Janssen Biotech Inc Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella
JP7479383B2 (ja) 2018-09-27 2024-05-08 エクシリオ デベロップメント， インコーポレイテッド マスクされたサイトカインポリペプチド
KR20210070300A (ko) 2018-10-03 2021-06-14 스태튼 바이오테크놀로지 비.브이. 사람 및 시노몰구스 ApoC3에 대해 특이적인 항체 및 이의 사용 방법
GB201816919D0 (en) 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
BR112021008057A2 (pt) 2018-10-30 2021-08-10 Genmab A/S método para tratar câncer cervical, e, kit
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
EP3876977A1 (de) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimäre antigen-rezeptoren für phagocytose
KR20210092769A (ko) 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 항-nkg2a 항체 및 그의 용도
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
CN113396158A (zh) 2018-11-26 2021-09-14 诺华股份有限公司 Lpl-gpihbp1融合多肽
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
EP3898993A1 (de) 2018-12-20 2021-10-27 Poseida Therapeutics, Inc. Nanotransposon-zusammensetzungen und verfahren zur verwendung
WO2020139926A2 (en) 2018-12-26 2020-07-02 Akrevia Therapeutics Inc. Anti-ctla4 antibodies and methods of use thereof
US20220098315A1 (en) 2019-01-11 2022-03-31 Novartis Ag Anti-cd40 antibodies for use in treatment of hidradenitis
AU2020208828A1 (en) 2019-01-15 2021-08-05 Janssen Biotech, Inc. Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
BR112021014106A2 (pt) 2019-01-22 2021-10-13 Bristol-Myers Squibb Company Anticorpos contra subunidade alfa de il-7r e usos dos mesmos
EA202192038A1 (ru) 2019-01-23 2021-10-05 Янссен Байотек, Инк. Композиции антител к фно для применения в способах лечения псориатического артрита
JP2020117502A (ja) 2019-01-28 2020-08-06 ファイザー・インク 変形性関節症の徴候および症状を処置する方法
WO2020160118A1 (en) 2019-01-29 2020-08-06 Shire-Nps Pharmaceuticals, Inc. Parathyroid hormone variants
CA3128097A1 (en) 2019-02-05 2020-08-13 Seagen Inc. Anti-cd228 antibodies and antibody-drug conjugates
EP3924386A4 (de) 2019-02-13 2023-01-04 The Brigham & Women's Hospital, Inc. Anti-peripherische lymphknoten ansprechende antikörper und verwendungen davon
EP3927430A1 (de) 2019-02-18 2021-12-29 Pfizer Inc. Verfahren zur behandlung von chronischen schmerzen im unteren rücken
EP4378958A2 (de) 2019-02-26 2024-06-05 Inspirna, Inc. Anti-mertk-antikörper mit hoher affinität und ihre verwendung
EP3938396A1 (de) 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos-antikörper zur behandlung von krebs
US20220153830A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
WO2020183270A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
EP3938384A4 (de) 2019-03-14 2022-12-28 Janssen Biotech, Inc. Herstellungsverfahren zur herstellung von anti-il12/il23-antikörperzusammensetzungen
WO2020188466A1 (en) 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
KR20220007086A (ko) 2019-05-08 2022-01-18 노파르티스 아게 T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체
CN114450022A (zh) 2019-05-14 2022-05-06 狼人治疗公司 分离部分及其使用方法
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
KR20220030952A (ko) 2019-06-03 2022-03-11 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
CN113939531A (zh) 2019-06-03 2022-01-14 詹森生物科技公司 用于治疗银屑病关节炎的抗tnf抗体组合物和方法
TW202112804A (zh) 2019-06-04 2021-04-01 瑞士商分子夥伴股份有限公司 多特異性蛋白質
US20220233709A1 (en) 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
US20220306727A1 (en) 2019-06-05 2022-09-29 Seagen Inc. Methods of Purifying Masked Antibodies
AU2020286444A1 (en) 2019-06-05 2021-12-23 Anaptysbio, Inc. PD-1 agonist and method of using same
MX2021015160A (es) 2019-06-12 2022-03-17 Novartis Ag Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.
CN114269372A (zh) 2019-06-27 2022-04-01 克里斯珀医疗股份公司 嵌合抗原受体t细胞和nk细胞抑制剂用于治疗癌症的用途
AU2020300002A1 (en) 2019-07-01 2022-02-24 Tonix Pharma Limited Anti-CD154 antibodies and uses thereof
EP3999538A1 (de) 2019-07-15 2022-05-25 Intervet International B.V. Caninisierte antikörper gegen canines ctla-4
CA3145347A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies to human and canine ctla-4
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20220242962A1 (en) 2019-08-12 2022-08-04 Aptevo Research And Development Llc 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021042019A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
EP4025593A1 (de) 2019-09-05 2022-07-13 Poseida Therapeutics, Inc. Zusammensetzungen allogener zellen und verfahren zur verwendung
JP2022553493A (ja) 2019-09-11 2022-12-23 ノバルティス アーゲー 患者におけるヒトウイルス関連障害を予防するための方法
RU2753282C2 (ru) 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
WO2021058091A1 (en) 2019-09-24 2021-04-01 Biontech Rna Pharmaceuticals Gmbh Treatment involving therapeutic antibody and interleukin-2 (il2)
US20210101982A1 (en) 2019-10-04 2021-04-08 Seattle Genetics, Inc. Anti-pd-l1 antibodies and antibody-drug conjugates
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3152623A1 (en) 2019-10-11 2021-04-15 Richard D. Cummings Anti-tn antibodies and uses thereof
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
EP4045528A1 (de) 2019-10-18 2022-08-24 Immunomic Therapeutics, Inc. Verbesserte lampenkonstrukte, die krebsantigene umfassen
EP4048692A2 (de) 2019-10-24 2022-08-31 NovaGo Therapeutics AG Neuartige anti-nogo-a-antikörper
BR112022008557A2 (pt) 2019-11-04 2022-08-09 Seagen Inc Conjugados de anticorpo-fármaco anti-cd30 e seu uso para o tratamento de infecção por hiv
WO2021091945A1 (en) 2019-11-05 2021-05-14 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy of multiple myeloma
WO2021091960A1 (en) 2019-11-05 2021-05-14 Jounce Therapeutics, Inc. Methods of treating cancer with anti-pd-1 antibodies
TW202132343A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
MX2022006073A (es) 2019-12-05 2022-08-04 Alector Llc Metodos para utilizar anticuerpos anti-trem2.
KR20220127243A (ko) 2019-12-12 2022-09-19 알렉터 엘엘씨 항-cd33 항체의 사용 방법
MX2022006578A (es) 2019-12-17 2022-07-04 Pfizer Anticuerpos especificos para cd47, pd-l1 y sus usos.
WO2021123091A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Canine interleukin-4 receptor alpha antibodies
MX2022007636A (es) 2019-12-20 2022-07-19 Intervet Int Bv Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
WO2021127505A1 (en) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
KR102653906B1 (ko) 2020-01-14 2024-04-03 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
WO2021150701A1 (en) 2020-01-21 2021-07-29 Bolt Biotherapeutics, Inc. Anti-pd-l1 antibodies
US20230069055A1 (en) 2020-01-21 2023-03-02 Bolt Biotherapeutics, Inc Anti-pd-l1 antibodies
WO2021148983A1 (en) 2020-01-24 2021-07-29 Pfizer Inc. Anti-e-selectin antibodies, compositions and methods of use
CN115279795A (zh) 2020-02-11 2022-11-01 克里斯珀医疗股份公司 靶向抗cd19嵌合抗原受体的抗独特型抗体
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
MX2022010021A (es) 2020-02-18 2022-11-09 Alector Llc Anticuerpos de pilra y sus metodos de uso.
CA3167851A1 (en) 2020-02-24 2021-09-02 Francesca CIGNARELLA Methods of use of anti-trem2 antibodies
BR112022017174A2 (pt) 2020-02-27 2022-10-18 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor
EP4110826A1 (de) 2020-02-28 2023-01-04 Shanghai Henlius Biotech, Inc. Anti-cd137-konstrukte, multispezifischer antikörper und dessen verwendungen
AU2021225920A1 (en) 2020-02-28 2022-09-15 Shanghai Henlius Biotech, Inc. Anti-CD137 construct and use thereof
WO2021178707A1 (en) 2020-03-04 2021-09-10 Poseida Therapeutics, Inc. Compositions and methods for the treatment of metabolic liver disorders
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
WO2021181233A2 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
CN115667308A (zh) 2020-04-03 2023-01-31 艾利妥 抗trem2抗体的使用方法
EP4126219A2 (de) 2020-04-04 2023-02-08 Takeda Pharmaceutical Company Limited Plasmakallikreinhemmer und verwendungen davon zur behandlung von akutem atemnotsyndrom
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
CN115996747A (zh) 2020-04-14 2023-04-21 波赛达治疗公司 用于治疗癌症的组合物和方法
JP2023521825A (ja) 2020-04-20 2023-05-25 ジョンス セラピューティクス， インコーポレイテッド ワクチン接種及び感染性疾患の治療のための組成物及び方法
EP4143227A2 (de) 2020-04-30 2023-03-08 Sairopa B.V. Anti-cd103 antikörper
WO2021222894A1 (en) 2020-05-01 2021-11-04 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibodies
EP3909601A1 (de) 2020-05-11 2021-11-17 LeukoCom GmbH Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
US20230272086A1 (en) 2020-05-12 2023-08-31 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. St2 antigen binding protein
AU2021271129A1 (en) 2020-05-14 2022-12-15 Molecular Partners Ag Multispecific proteins
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
PE20231376A1 (es) 2020-05-17 2023-09-07 Astrazeneca Uk Ltd Anticuerpos contra el sars-cov-2 y metodos e seleccion y uso de los mismos
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
BR112022024629A2 (pt) 2020-06-02 2023-02-23 Dynamicure Biotechnology Llc Construtos anti-cd93 e seus usos
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
US20230242624A1 (en) 2020-06-02 2023-08-03 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
WO2021245603A1 (en) 2020-06-04 2021-12-09 Crispr Therapeutics Ag Anti-cd70 antibodies and uses thereof
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
EP4171585A1 (de) 2020-06-26 2023-05-03 CRISPR Therapeutics AG Allogene zelltherapie von b-zell-malignomen mit genetisch manipulierten, auf cd19 abzielenden t-zellen
KR20230028492A (ko) 2020-06-29 2023-02-28 젠맵 에이/에스 항-조직 인자 항체-약물 접합체 및 암의 치료에서의 그의 용도
IT202000015754A1 (it) 2020-06-30 2021-12-30 Fond Toscana Life Sciences Antibodies to coronavirus
WO2022003530A1 (en) 2020-06-30 2022-01-06 Fondazione Toscana Life Sciences Neutralizing antibodies to sars coronavirus-2
EP4182335A2 (de) 2020-07-14 2023-05-24 Pfizer Inc. Rekombinantes vacciniavirus
EP4182346A1 (de) 2020-07-17 2023-05-24 Pfizer Inc. Therapeutische antikörper und deren verwendungen
KR20230038783A (ko) 2020-07-20 2023-03-21 아스트라제네카 유케이 리미티드 Sars-cov-2 단백질, 항-sars-cov-2 항체, 및 이를 사용하는 방법
WO2022020456A2 (en) 2020-07-21 2022-01-27 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
MX2023001055A (es) 2020-07-24 2023-03-17 Amgen Inc Inmunógenos derivados de la proteína de la espícula del sars-cov2.
EP4188550A1 (de) 2020-07-29 2023-06-07 Dynamicure Biotechnology LLC Anti-cd93 konstrukte und deren verwendungen
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
WO2022026832A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
IL300176A (en) 2020-08-04 2023-03-01 Seagen Inc Anti-CD228 antibodies and antibody-drug conjugates
WO2022031804A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Improved methods and kits for detecting sars-cov-2 protein in a sample
WO2022029629A1 (en) 2020-08-04 2022-02-10 Crispr Therapeutics Ag Anti-idiotype antibodies targeting anti-cd70 chimeric antigen receptor
IL300660A (en) 2020-08-18 2023-04-01 Cephalon Llc Antibodies against PAR-2 and methods of using them
US20220064335A1 (en) 2020-08-25 2022-03-03 Crispr Therapeutics Ag Anti-idiotype antibodies targeting anti-bcma chimeric antigen receptor
KR20230060514A (ko) 2020-09-01 2023-05-04 다케다 야쿠힌 고교 가부시키가이샤 인터루킨-2 뮤테인 및 이의 용도
WO2022051549A1 (en) 2020-09-04 2022-03-10 Rutgers, The State University Of New Jersey Sars-cov-2 vaccines and antibodies
JP2023541456A (ja) 2020-09-14 2023-10-02 ブイオーアール バイオファーマ インコーポレーテッド がん治療用キメラ抗原受容体
AU2021358662A1 (en) 2020-10-09 2023-05-04 Children's Medical Center Corporation CD1a ANTIBODIES AND USES THEREOF
KR20230112616A (ko) 2020-10-13 2023-07-27 아비타이드 엘엘씨 3중-나선 번들 단백질들의 친화성 리간드 라이브러리 및 이의 용도
US20230391829A1 (en) 2020-10-13 2023-12-07 Avitide LLC Aav8 affinity agents
MX2023004438A (es) 2020-10-15 2023-05-08 Intervet Int Bv Anticuerpos de rata caninizados para el receptor alfa de interleucina-31 canino.
US20240000969A1 (en) 2020-10-21 2024-01-04 Poseida Therapeutics San Diego Compositions and methods for delivery of nucleic acids
US20230391872A1 (en) 2020-10-23 2023-12-07 Anaptysbio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
US20240002509A1 (en) 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
US20230399403A1 (en) 2020-11-11 2023-12-14 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
US20240024320A1 (en) 2020-11-17 2024-01-25 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
IL303328A (en) 2020-12-01 2023-07-01 Aptevo Res & Development Llc CD3-binding bispecific and heterodimeric antibodies to PSMA
WO2022116086A1 (en) 2020-12-03 2022-06-09 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
KR20230118904A (ko) 2020-12-11 2023-08-14 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Sfrp2 길항제를 포함하는 조성물 및 방법
EP4259661A1 (de) 2020-12-14 2023-10-18 Novartis AG Reverse bindemittel für anti-natriuretische peptidrezeptor-1 (npr1)-antikörper und verwendungen davon
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
US20240101654A1 (en) 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
JP2024505075A (ja) 2021-01-29 2024-02-02 アロジーン セラピューティクス，インコーポレイテッド 同種細胞産物のＴ細胞認識を軽減するための、ＴＡＰ２、ＮＬＲＣ５、β２ｍ、ＴＲＡＣ、ＲＦＸ５、ＲＦＸＡＰ及びＲＦＸＡＮＫのうち１つ以上のノックダウン又はノックアウト
WO2022178396A1 (en) 2021-02-19 2022-08-25 Avitide LLC Aav2 affinity agents
AU2022227607A1 (en) 2021-02-23 2023-08-24 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
US20240060090A1 (en) 2021-02-23 2024-02-22 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
TW202317612A (zh) 2021-03-01 2023-05-01 美商艾希利歐發展股份有限公司 用於治療癌症的ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
JP2024508488A (ja) 2021-03-01 2024-02-27 エクシリオ デベロップメント， インコーポレイテッド がんを治療するためのマスクされたｃｔｌａ４及びｐｄ１／ｐｄ－ｌ１抗体の組み合わせ
EP4301772A1 (de) 2021-03-04 2024-01-10 Allogene Therapeutics, Inc. Fasl expression und fasr gen knockout zum schutz von therapeutischen zellen vor allogener abstossung und aktivierung induziertem zelltod
WO2022187671A1 (en) 2021-03-04 2022-09-09 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
JP2024509191A (ja) 2021-03-05 2024-02-29 ダイナミキュア バイオテクノロジー エルエルシー 抗ｖｉｓｔａ構築物およびその使用
CN117751138A (zh) 2021-03-12 2024-03-22 詹森生物科技公司 用抗il23特异性抗体治疗银屑病关节炎的安全且有效的方法
KR20230156764A (ko) 2021-03-12 2023-11-14 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체에 의해 tnf 요법에 부적절한 반응을 보이는 건선성 관절염 환자를 치료하는 방법
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
EP4171622B1 (de) 2021-03-23 2024-05-01 King's College London Zusammensetzungen mit nkg2d, cxcr2 und dap10/dap12 fusionspolypeptiden und verfahren zur verwendung davon
EP4314049A1 (de) 2021-03-25 2024-02-07 Dynamicure Biotechnology LLC Anti-igfbp7-konstrukte und verwendungen davon
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
AU2022244125A1 (en) 2021-03-26 2023-10-19 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
EP4314068A1 (de) 2021-04-02 2024-02-07 The Regents Of The University Of California Antikörper gegen gespaltenes cdcp1 und verwendungen davon
EP4320159A1 (de) 2021-04-09 2024-02-14 Celldex Therapeutics, Inc. Antikörper gegen ilt4, bispezifische anti-ilt4/pd-l1-antikörper und verwendungen davon
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
AR125851A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas
WO2022238963A2 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating solid tumors
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
WO2022262959A1 (en) 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3
US20220409665A1 (en) 2021-06-15 2022-12-29 Allogene Therapeutics, Inc. Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence
EP4355785A1 (de) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3-konstrukte und verwendungen davon
EP4357361A1 (de) 2021-06-18 2024-04-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anti-il-36r-antikörper und verwendung davon
WO2023278377A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
US20230042465A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
EP4367138A1 (de) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Herstellungsverfahren zur herstellung von anti-il12/il23-antikörperzusammensetzungen
KR20240034218A (ko) 2021-07-09 2024-03-13 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생산하기 위한 제조 방법
EP4370211A1 (de) 2021-07-14 2024-05-22 Seagen Inc. Antikörpermaskierende domänen
WO2023007374A1 (en) 2021-07-27 2023-02-02 Pfizer Inc. Method of treatment of cancer pain with tanezumab
WO2023010118A1 (en) 2021-07-29 2023-02-02 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
CA3227716A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
AU2022331122A1 (en) 2021-08-20 2024-02-15 Intervet International B.V. Homodimer fusion proteins for treating atopic dermatitis
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
WO2023060088A1 (en) 2021-10-04 2023-04-13 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
AU2022358729A1 (en) 2021-10-04 2024-04-11 Poseida Therapeutics, Inc. Transposases and uses thereof
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
TW202323282A (zh) 2021-10-15 2023-06-16 美商賽特艾克斯生物製藥公司 可活化之多肽複合物
TW202330611A (zh) 2021-10-15 2023-08-01 美商賽特艾克斯生物製藥公司 可活化之多肽複合物
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023076989A1 (en) 2021-10-29 2023-05-04 Seagen Inc. Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
WO2023079430A1 (en) 2021-11-02 2023-05-11 Pfizer Inc. Methods of treating mitochondrial myopathies using anti-gdf15 antibodies
CA3237341A1 (en) 2021-11-04 2023-05-11 Nanjing Legend Biotech Co., Ltd. Bcma-targeted car-t cell therapy for multiple myeloma
WO2023077343A1 (en) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2023091968A1 (en) 2021-11-17 2023-05-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023100153A1 (en) 2021-12-03 2023-06-08 Crispr Therapeutics Ag Use of anti-cd70 antibodies for identifying subjects susceptible for treatment with nk cell-based anti-cd70 therapy
GB202118201D0 (en) 2021-12-15 2022-01-26 King S College London Engineered immune cell
WO2023111157A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized and felinized antibodies to human ngf
WO2023111128A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha ii
WO2023122327A2 (en) 2021-12-24 2023-06-29 Avitide LLC Chi domain affinity ligands and agents
WO2023137460A1 (en) 2022-01-14 2023-07-20 Saccharo, Inc. De-n-acetylated polysialic acid (dpsa) binding agent and method of using same
WO2023141576A1 (en) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2023154678A1 (en) 2022-02-08 2023-08-17 Amgen Inc. Codon-optimized nucleic acids encoding ocrelizumab
GB202201927D0 (en) 2022-02-14 2022-03-30 Kings College Artificial microrna construct
WO2023164516A1 (en) 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies
WO2023164573A1 (en) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
WO2023164695A2 (en) 2022-02-28 2023-08-31 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
WO2023180533A1 (en) 2022-03-25 2023-09-28 Les Laboratoires Servier Anti-gal3 antibodies and compositions
US20230346934A1 (en) 2022-03-29 2023-11-02 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
WO2023187657A1 (en) 2022-03-30 2023-10-05 Novartis Ag Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
WO2023193239A1 (en) 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof
WO2023212611A1 (en) 2022-04-27 2023-11-02 Anaptysbio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
US20240059799A1 (en) 2022-05-11 2024-02-22 Pfizer Inc. Anti-tl1a antibodies and methods of use thereof
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
US11932693B2 (en) 2022-05-12 2024-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
WO2023228082A1 (en) 2022-05-26 2023-11-30 Pfizer Inc. Anti-tnfr2 antibodies and methods of use thereof
WO2023233330A1 (en) 2022-05-31 2023-12-07 Pfizer Inc. Anti-bmp9 antibodies and methods of use thereof
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
WO2023242372A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn/hsa binding molecules and methods of use
WO2023242769A1 (en) 2022-06-17 2023-12-21 Pfizer Inc. Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
TW202405020A (zh) 2022-07-29 2024-02-01 美商阿列克特有限責任公司 轉鐵蛋白受體抗原結合域及其用途
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024025911A1 (en) 2022-07-29 2024-02-01 Avitide LLC An affinity agent comprising a ligand that binds vce and comprises seq id no: 1
WO2024028773A1 (en) 2022-08-03 2024-02-08 Pfizer Inc. Anti- il27r antibodies and methods of use thereof
WO2024036273A1 (en) 2022-08-11 2024-02-15 Poseida Therapeutics, Inc. Chimeric cd8-alpha co-receptor compositions and methods of use
WO2024038187A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Assay for detection of il-33
WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
WO2024092038A2 (en) 2022-10-25 2024-05-02 Ablexis, Llc Anti-cd3 antibodies
WO2024097816A1 (en) 2022-11-03 2024-05-10 Seagen Inc. Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
WO2024102760A2 (en) 2022-11-07 2024-05-16 Anaptysbio, Inc. Cd 122 binding agents and method of using same
WO2024107731A2 (en) 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4797359A (en) * 1983-05-10 1989-01-10 Board Of Regents, The University Of Texas System Heat shock regulated production of selected and fused proteins in yeast
WO1986002097A1 (en) * 1984-10-01 1986-04-10 The General Hospital Corporation Plant cells resistant to herbicidal glutamine synthetase inhibitors
JPS62502662A (ja) * 1985-05-01 1987-10-15 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 外来性ｄｎａの高レベル増幅および発現
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences

Also Published As

Publication number Publication date
WO1987004462A1 (en) 1987-07-30
EP0256055B1 (de) 1991-08-28
CA1338901C (en) 1997-02-11
EP0256055A1 (de) 1988-02-24
AU6893587A (en) 1987-08-14
GB8601597D0 (en) 1986-02-26
US5827739A (en) 1998-10-27
JPH0732712B2 (ja) 1995-04-12
JPS63502955A (ja) 1988-11-02
US5122464A (en) 1992-06-16
AU599081B2 (en) 1990-07-12
ATE66693T1 (de) 1991-09-15
US5770359A (en) 1998-06-23

Similar Documents

Publication Publication Date Title
DE3772485D1 (de) Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben.
ES2009238A6 (es) Metodo para producir proteinas de mycobacterium tuberculosis y peptidos antigenicos de las mismas.
DE3854952D1 (de) Mykobakterielle rekombinanten und peptide
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
EP1092771A3 (de) Tetracyclin-regulierte Transcriptionsmodulatoren
CA2169854A1 (en) Enhanced expression in plants using non-translated leader sequences
LTIP828A (en) Nucleic acid fragment which codes for human proapolipoprotein a-1
DE3788524T3 (de) Verfahren zur Herstellung von Proteinprodukten in Aspergillus Oryzae und in Aspergillus zu verwendender Promotor.
NO20015587L (no) Ekspresjon og eksport av interferon-<alfa> proteiner som Fc fusjonsproteiner
DE69333815D1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
ES8207514A1 (es) Un procedimiento para la preparacion de interferon
ES8802182A1 (es) Un procedimiento para preparar una linfotoxina.
ATE46536T1 (de) Verfahren zur herstellung von reifen proteinen in wirtzellen von wirbeltieren.
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE42114T1 (de) Mikrobiologisch hergestelltes interferon alpha2(arg), dna-sequenz, die fuer dieses interferon codiert, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung.
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
DE50015992D1 (de) Für den Export verzweigtkettiger Aminosäuren kodierende Nukleotidsequenzen, Verfahren zu deren Isolierung und ihre Verwendung
SI9500270B (sl) Rekombinantni mersacidin in postopek za izdelavo
DE69026716D1 (de) Nukleinsäurefragmente von einem genom eines geeigneten mykobakteriums, ihre verwendung zur diagnose von mykobakterieninfektionen sowie diese fragmente enthaltende plasmide
DE3583634D1 (de) Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens.
JPS6420095A (en) Polypeptide having anti-blood coagulating action
ATE89317T1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
Weinstein Comparative studies on the genetic code
DK1136559T3 (da) Nukleotidsekvenser, der koder for dapC-genet, og fremgangsmåde til fremstilling af L-lysin
ATE43139T1 (de) Klonierungs- und expressionsvektoren fuer gammainterferon, transformierte bakterien und verfahren zur herstellung von gamma-interferon.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition